Modulation of the megakaryoblastic Dami cell line differentiation by phosphodiesterase inhibitors and imidazo[1,2-a]pyrazine derivatives

Pharmacology and Toxicology

Volumn 80, Issue 6, 1997, Pages 286-289

  Zurbonsen, Katja ^a,b   Michel, Alain ^b   Vittet, Daniel ^a   Bonnet, Pierre Antoine ^b   Chevillard, Claude ^a  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 6 BROMO 8 METHYLAMINOIMIDAZO[1,2 A]PYRAZINE 2 CARBONITRILE; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; IMIDAZOPYRAZINE DERIVATIVE; ISOBUTYLMETHYLXANTHINE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; ZAPRINAST;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEGAKARYOBLAST; PRIORITY JOURNAL;

EID: 0030955407     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1997.tb01975.x     Document Type: Article

References (14)

1. Bang, B. E., C. Ericsen & J. Aarbakke: Effects of cAMP and cGMP elevating agents on HL-60 cell differentiation. Pharmacol. Toxicol. 1994, 75, 108-112.
2. Beavo, J. A. & D. H. Reifsnyder: Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol. Sci. 1990, 11, 150-155.
3. Bonnet, P. A., A. Michel, F. Laurent, C. Sablayrolles, E. Rechencq, J. C. Mani, M. Boucard & J. P. Chapat: Synthesis and antibronchospastic activity of 8-alkoxy- and 8-(alkylamino)imidazo[1,2-α]-pyrazine. J. Med. Chem. 1992, 35, 3353-3358.
4. Boss, G. R.: cGMP-induced differentiation of the promyelocytic cell-line HL-60. Proc. Natl. Acad. Sci. USA 1989, 86, 7174-7178.
5. Chaplinski, T. J. & J. E. Niedel: Cyclic nucleotide-induced maturation of human promyelocytic leukemia cells. J. Clin. Invest. 1982, 70, 953-964.
6. Cho-Chung, Y. S.: Role of cyclic AMP receptor proteins in growth, differentiation and suppression of malignancy: new approches to therapy. Cancer Res. 1990, 50, 7093-7100.
7. Elks, M. L. & V. C. Manganiello: A role for soluble cAMP phosphodiesterase in differentiation of 3T3-L1 adipocytes. J. Cell. Physiol. 1985, 124, 191-198.
8. Greenberg, S. M., D. S. Rosenthal, T. A. Greeley, R. Tantravahi & R. I. Handin: Characterization of a new megakaryocytic cell line: The Dami cell. Blood 1988, 72, 1968-1977.
9. Parsons, W. J., V. Ramkumar & G. L. Stiles: Isobutylmethylxanthine stimulates adenylate cyclase by blocking the inhibitory regulatory protein, Gi. Mol. Pharmacol. 1988, 34, 37-41.
10. Tomes, C., S. Rossi & S. Moreno: Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity. Cell Signal. 1993, 5, 615-621.
11. Vittet, D., C. Duperray & C. Chevillard: Cyclic-AMP inhibits cell growth and negatively interacts with platelet membrane glycoprotein expression on the Dami human megakaryoblastic cell line. J. Cell. Physiol. 1995, 163, 645-655.
12. Zurbonsen, K., C. Chevillard, D. Vittet, P. A. Bonnet & A. Michel: Inhibition of human erythroleukemia (HEL) cell proliferation by imidazo[1,2-a]pyrazine derivatives. Fundam. Clin. Pharmacol. 1994, 8, 260.
13. Zurbonsen, K., A. Michel, D. Vittet, P. A. Bonnet & C. Chevillard: Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on Dami cell line. Biochem. Pharmacol. 1997a, in press.
14. Zurbonsen, K., A. Michel, D. Vittet, P. A. Bonnet & C. Chevillard: Antiproliferative effects of imidazo[1.2-a]pyrazine on the Dami cell line. Biochem. Pharmacol. 1997b, in press.